8 completed, 5 active not recruiting, 4 terminated, 2 withdrawn. 20 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 20 | Completed 8, Active not recruiting 5, Terminated 4, Withdrawn 2, Unknown 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Progesterone Receptor Negative: new trials by email Literature Review of Progesterone Receptor Negative trials Research Report on Progesterone Receptor Negative
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Atorvastatin, Capecitabine - Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 6 | 2019-09-23 | 2024-10-02 |
| Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Pembrolizumab, Cisplatin - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Withdrawn | University of Washington | 2019-04-01 | 2019-04-26 | |
| Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Glembatumumab Vedotin, Ipilimumab, Laboratory Biomarker Analysis - Advanced Malignant Solid Neoplasm, Estrogen Receptor Negative | Phase 1 / Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2018-04-20 | 2018-07-18 | |
| Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | Northwestern University | 12 | 2017-09-14 | 2026-06-17 |
| Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer Mirvetuximab Soravtansine - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8 | Phase 2 | Completed | M.D. Anderson Cancer Center | 96 | 2017-06-05 | 2020-12-02 |
| Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Enobosarm, Laboratory Biomarker Analysis, Pembrolizumab - Androgen Receptor Positive, Estrogen Receptor Negative | Phase 2 | Completed | City of Hope Medical Center | 18 | 2017-06-01 | 2024-02-20 |
| Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Capecitabine, Laboratory Biomarker Analysis, Pembrolizumab - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Unknown | Northwestern University | 30 | 2017-05-25 | 2020-07-13 |
| Neoadjuvant Pembrolizumab + Decitabine Followed by Std Neoadj Chemo for Locally Advanced HER2- Breast Ca Doxorubicin, Cyclophosphamide, Paclitaxel - Breast Adenocarcinoma, Estrogen Receptor- Negative Breast Cancer | Phase 2 | Active not recruiting | Virginia Commonwealth University | 46 | 2017-01-24 | 2026-07-01 |
| Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer Carboplatin, Laboratory Biomarker Analysis, Paclitaxel - Breast Carcinoma, Breast Lump | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 42 | 2016-10-06 | 2026-10-06 |
| Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis Cognitive Assessment, Palbociclib, Quality-of-Life Assessment - Breast Carcinoma Metastatic in the Brain, Estrogen Receptor Negative | Phase 2 | Terminated | Northwestern University | 12 | 2016-08-31 | 2020-04-14 |
| FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy Computed Tomography, F-18 16 Alpha-Fluoroestradiol, Laboratory Biomarker Analysis - HER2/Neu Negative, Progesterone Receptor Negative | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 99 | 2016-05-04 | 2026-06-29 |
| Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Anastrozole, Doxorubicin Hydrochloride, Exemestane - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | City of Hope Medical Center | 30 | 2016-03-28 | 2024-03-19 |
| 18F-FSPG PET/CT for Cancer Patients on Therapy 18F-FSPG, 18F-FDG - B-Cell Neoplasm, Estrogen Receptor Negative | Phase 2 | Completed | Andrei Iagaru | 7 | 2015-07-01 | 2019-01-03 |
| Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy Laboratory Biomarker Analysis, Pembrolizumab - Edema, Erythema | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 71 | 2015-06-11 | 2026-07-15 |
| Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Biomarker Analysis, Enzalutamide, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 1 / Phase 2 | Terminated | Vanderbilt-Ingram Cancer Center | 30 | 2015-06-01 | 2022-08-22 |
| Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 37 | 2013-10-02 | 2019-09-20 |
| Paclitaxel & Cyclophosphamide With or Without Trastuzumab Before Surgery in Treating Previously Untreated Breast Cancer Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Completed | University of Nebraska | 92 | 2012-12-07 | 2026-06-26 |
| Tivantinib in Treating Patients With Recurrent or Metastatic Breast Cancer Laboratory Biomarker Analysis, Tivantinib - Estrogen Receptor Negative, HER2/Neu Negative | Phase 2 | Completed | National Cancer Institute (NCI) | 22 | 2012-03-01 | 2016-03-21 |
| Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer carboplatin, paclitaxel albumin-stabilized nanoparticle formulation, laboratory biomarker analysis - Inflammatory Breast Cancer, Stage IIA Breast Cancer | Phase 2 | Active not recruiting | City of Hope Medical Center | 67 | 2012-02-15 | 2026-03-30 |
| MK2206 in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer Akt Inhibitor MK2206, Therapeutic Conventional Surgery, Pharmacological Study - Estrogen Receptor Negative, Estrogen Receptor Positive | Phase 2 | Terminated | National Cancer Institute (NCI) | 12 | 2011-04-01 | 2017-08-30 |
Triple Negative Breast Neoplasms (18) · Breast Neoplasms (16) · Inflammatory Breast Neoplasms (4) · Edema (2) · Erythema (2) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Lymphoma, B-Cell (1) · Melanoma (1) · Mesothelioma (1) · Neoplasm Metastasis (1) · Uveal Melanoma (1)
Breast Diseases (19) · Neoplasms (19) · Neoplasms by Site (19) · Skin Diseases (19) · Skin and Connective Tissue Diseases (19) · Breast Neoplasms (3) · Pathological Conditions, Signs and Symptoms (3) · Neoplasms by Histologic Type (2) · Signs and Symptoms (2) · Skin Manifestations (2) · Adenocarcinoma (1) · Adenoma (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1)
pembrolizumab (7) · Carboplatin (4) · Doxorubicin (3) · Paclitaxel (3) · Taxes (3) · Albumin-Bound Paclitaxel (2) · Capecitabine (2) · Cyclophosphamide (2) · PF-05280014 (2) · Trastuzumab (2) · (4S)-4-(3-(18F)fluoropropyl)-L-glutamate (1) · 130-nm albumin-bound paclitaxel (1) · 16-fluoroestradiol (1) · 2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide (1) · 4-(3-fluoropropyl)glutamic acid (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (4) · City of Hope Medical Center (3) · Northwestern University (3) · Andrei Iagaru (1) · University of Nebraska (1) · University of Washington (1) · Vanderbilt-Ingram Cancer Center (1) · Virginia Commonwealth University (1)
United States (19)
Amulya C Yellala, MD (1) · Andrei M Iagaru, MD (1) · Azadeh Nasrazadani (1) · Bhuvaneswari Ramaswamy, MD (1) · Bora Lim, MD (1) · Carlos H Barcenas (1) · Cristofanilli Massimo, MD (1) · Farrokh Dehdashti (1) · Haeseong Park (1) · Harry D. Bear, M.D., Ph.D. (1) · James Waisman, MD (1) · Jennifer Specht, MD (1) · Joanne Mortimer, MD, PhD (1) · Kevin Kalinsky (1) · Massimo Cristofanilli, MD (1)
PMID 26123926, PMID 32060053, PMID 37294342, PMID 39558017
P30CA060553 (3), N01CM00070 (1), N01CM00100 (1), N01CM62204 (1), P30CA006516 (1), P30CA013330 (1), P30CA016058 (1), P30CA016059 (1), P30CA036727 (1), P30CA068485 (1), P30CA124435 (1), U01CA062490 (1), U10CA180820 (1), UM1CA186704 (1), UM1CA186712 (1)